Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

820.68
Delayed Data
As of Mar 24
 +17.84 / +2.22%
Today’s Change
538.01
Today|||52-Week Range
824.00
+13.75%
Year-to-Date
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
Mar 25 / MotleyFool.com - Paid Partner Content
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Mar 23 / Zacks.com - Paid Partner Content
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Mar 24 / Zacks.com - Paid Partner Content
Regeneron (REGN) Gets Label Extension for Cholesterol Drug
Mar 22 / Zacks.com - Paid Partner Content
Wall Street Has High Hopes for These 2 Nasdaq Stocks
Mar 24 / MotleyFool.com - Paid Partner Content
Regeneron (REGN) Gains But Lags Market: What You Should Know
Mar 21 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Mar 24 / Zacks.com - Paid Partner Content
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Mar 21 / Zacks.com - Paid Partner Content
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
Mar 24 / Zacks.com - Paid Partner Content
Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?
Mar 17 / Zacks.com - Paid Partner Content
Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?
Mar 24 / Zacks.com - Paid Partner Content
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
Mar 15 / Zacks.com - Paid Partner Content
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study
Mar 23 / Zacks.com - Paid Partner Content
Should You Invest in the iShares Biotechnology ETF (IBB)?
Mar 14 / Zacks.com - Paid Partner Content
Why Shares of Regeneron Are Rising Thursday
Mar 23 / MotleyFool.com - Paid Partner Content